Vaxcyte Raises $816.5 Million in Public Offering of Common Stock and Pre-Funded Warrants

Vaxcyte, Inc.

Underwriting agreement with BofA, Jefferies, Leerink, Evercore for 10,937,500 shares at $64.00 per share and 781,250 pre-funded warrants at $63.999 per warrant.
Pre-funded warrants have an exercise price of $0.001 per share and are exercisable until fully exercised subject to an ownership limitation.
Underwriters exercised option in full for an additional 1,757,812 shares, bringing total shares offered to 12,695,312.
Net proceeds expected to be approximately $816.5 million after underwriting discounts and expenses.
Closing expected on or about February 2, 2024, under effective registration statement on Form S-3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.